Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibers and central neurons, and affects 7–10% of the general population. Neuropathic pain may result from disorders of the peripheral nervous system or the central nervous system (brain and spinal cord). Thus, neuropathic pain may be divided into peripheral neuropathic pain, central neuropathic pain, or mixed (peripheral and central) neuropathic pain.
Medications used to treat neuropathic pain include over-the-counter analgesics, anticonvulsants, tricyclic antidepressants (TCAs), topical anesthetic agents, nonsteroidal anti-inflammatory drugs (NSAIDs), antiarrhythmics, narcotic analgesics, and opioids.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
The Chronic Neuropathic Pain market report also covers emerging drugs, current treatment practices, Chronic Neuropathic Pain market share of the individual therapies, current and forecasted Chronic Neuropathic Pain Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Chronic Neuropathic Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Chronic Neuropathic Pain Market Key Facts
-
According to an article by Melillo (2020), published in the American Journal of Managed Care, in France, the prevalence of chronic neuropathic pain is around 6.9%.
-
As per the article by Yu et al. (2020), titled “Neuromodulation Management of Chronic Neuropathic Pain in the Central Nervous System,” chronic neuropathic pain is a widespread condition that affects 7–8% of the total population.
-
As per the article by Posso et al. (2016) titled, “Epidemiology of neuropathic pain,” a study of the German population has shown that in general 6.5% of respondents have reported pain with chronic neuropathic pain characteristics, and have reported higher intensity and more interference of pain in their daily activities as compared to individuals with chronic non-neuropathic pain.
-
According to a study by Posso et al. (2016), it is known that chronic neuropathic pain is more prevalent among females of older ages.
Key Benefits of Chronic Neuropathic Pain Market Report
-
Chronic Neuropathic Pain market report provides an in-depth analysis of Chronic Neuropathic Pain Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Chronic Neuropathic Pain market report will help in developing business strategies by understanding the Chronic Neuropathic Pain Market trends & developments, key players, and future market competition that will shape and drive the Chronic Neuropathic Pain market in the upcoming years.
-
The Chronic Neuropathic Pain market report covers Chronic Neuropathic Pain current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Chronic Neuropathic Pain market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Chronic Neuropathic Pain Market
The Chronic Neuropathic Pain market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Chronic Neuropathic Pain market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Chronic Neuropathic Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Chronic Neuropathic Pain Epidemiology
The Chronic Neuropathic Pain epidemiology section covers insights about the historical and current Chronic Neuropathic Pain patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chronic Neuropathic Pain Drugs Uptake and Key Market Players
The Chronic Neuropathic Pain Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Neuropathic Pain market or expected to get launched in the market during the study period. The analysis covers the Chronic Neuropathic Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Chronic Neuropathic Pain market is anticipated to change in the coming years owing to the launch of upcoming therapies.
Chronic Neuropathic Pain Companies:
MedinCell
Kineta
Pfizer
Algiax Pharmaceuticals
Centrexion Therapeutics
And many others.
Chronic Neuropathic Pain therapies covered in the report include:
AP-325
CNTX-6016
Lyrica
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Chronic Neuropathic Pain Competitive Intelligence Analysis
4. Chronic Neuropathic Pain Market Overview at a Glance
5. Chronic Neuropathic Pain Disease Background and Overview
6. Chronic Neuropathic Pain Patient Journey
7. Chronic Neuropathic Pain Epidemiology and Patient Population
8. Chronic Neuropathic Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Neuropathic Pain Unmet Needs
10. Key Endpoints of Chronic Neuropathic Pain Treatment
11. Chronic Neuropathic Pain Marketed Products
12. Chronic Neuropathic Pain Emerging Therapies
13. Chronic Neuropathic Pain Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Neuropathic Pain Market Outlook (7 major markets)
16. Chronic Neuropathic Pain Access and Reimbursement Overview
17. KOL Views on the Chronic Neuropathic Pain Market.
18. Chronic Neuropathic Pain Market Drivers
19. Chronic Neuropathic Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Related Reports
Chronic Neuropathic Pain Epidemiology Forecast
DelveInsight's Chronic Neuropathic Pain- Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Chronic Neuropathic Pain in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Latest BioPharma Blog - Parkinson’s Disease Therapeutics Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
